What is NDC 62542-025?

62542-025 is the product NDC for Amphetamine Extended-Release, Amphetamine 15.7 mg/1 tablet, orally disintegrating, listed with the FDA by Neos Therapeutics, LP. It has 1 package NDC, shown above in 10- and 11-digit form.

Neos Therapeutics, LP, NDC labeler code 62542. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Amphetamine Extended-Release?

5 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Amphetamine Extended-Release NDC 62542-025

NDC codes

FDA NDC Directory

Product NDC (as listed)62542-025Labeler and product segments. Claims need a package NDC.

Product NDC at billing width62542-0025Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
62542-025-30	62542002530	30 BLISTER PACK in 1 CARTON (62542-025-30) / 6 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACKMarketed from Sep 1, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Amphetamine Extended-Release
Generic name (nonproprietary): amphetamine extended-release
Active ingredients: Amphetamine — 15.7 mg/1
Dosage form: Tablet, Orally disintegrating
Route: Oral
Labeler: Neos Therapeutics, LPNDC labeler code 62542
Product type: Prescription drug
Marketing category: NDA authorized genericApplication NDA 204326
Marketing start: Sep 1, 2025
Listing expires: Dec 31, 2027
DEA schedule: CII
Other FDA classes: Central Nervous System Stimulation (Physiologic effect)
Identifiers: Product ID 62542-025_51ddc66d-2364-ecd2-e063-6294a90ad067SPL ID 51ddc66d-2364-ecd2-e063-6294a90ad067
Pharmacologic class: Central Nervous System Stimulant

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N462542002530 followed by a unit qualifier and the quantity

Package 62542-0025-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

The FDA listing for this product does not reference a label (SPL) set.

About NDC 62542-025

What is NDC 62542-025?: 62542-025 is the product NDC for Amphetamine Extended-Release, Amphetamine 15.7 mg/1 tablet, orally disintegrating, listed with the FDA by Neos Therapeutics, LP. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Amphetamine Extended-Release.
What is the active ingredient?: Amphetamine.
Who is the labeler?: Neos Therapeutics, LP, NDC labeler code 62542. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Amphetamine Extended-Release?: 5 other product NDCs are listed under this name. See all Amphetamine Extended-Release NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Amphetamine Extended-Release NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Amphetamine Extended-Release	Amphetamine 3.1 mg/1	Tablet, Orally disintegratingOral	Neos Therapeutics, LP	62542-005	62542-0005-30
Amphetamine Extended-Release	Amphetamine 6.3 mg/1	Tablet, Orally disintegratingOral	Neos Therapeutics, LP	62542-010	62542-0010-30
Amphetamine Extended-Release	Amphetamine 9.4 mg/1	Tablet, Orally disintegratingOral	Neos Therapeutics, LP	62542-015	62542-0015-30
Amphetamine Extended-Release	Amphetamine 12.5 mg/1	Tablet, Orally disintegratingOral	Neos Therapeutics, LP	62542-020	62542-0020-30
Amphetamine Extended-Release	Amphetamine 18.8 mg/1	Tablet, Orally disintegratingOral	Neos Therapeutics, LP	62542-030	62542-0030-30

Other NDCs under NDA 204326

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 204326
Product	Strength	Form · route	Labeler	Product NDC
Amphetamine Extended-Release	Amphetamine 3.1 mg/1	Tablet, Orally disintegratingOral	Neos Therapeutics, LP	62542-005
Amphetamine Extended-Release	Amphetamine 6.3 mg/1	Tablet, Orally disintegratingOral	Neos Therapeutics, LP	62542-010
Amphetamine Extended-Release	Amphetamine 9.4 mg/1	Tablet, Orally disintegratingOral	Neos Therapeutics, LP	62542-015
Amphetamine Extended-Release	Amphetamine 12.5 mg/1	Tablet, Orally disintegratingOral	Neos Therapeutics, LP	62542-020
Amphetamine Extended-Release	Amphetamine 18.8 mg/1	Tablet, Orally disintegratingOral	Neos Therapeutics, LP	62542-030
Adzenys XR-ODTamphetamine	Amphetamine 3.1 mg/1	Tablet, Orally disintegratingOral	Neos Therapeutics Brands, LLC	70165-005
Adzenys XR-ODTamphetamine	Amphetamine 6.3 mg/1	Tablet, Orally disintegratingOral	Neos Therapeutics Brands, LLC	70165-010
Adzenys XR-ODTamphetamine	Amphetamine 9.4 mg/1	Tablet, Orally disintegratingOral	Neos Therapeutics Brands, LLC	70165-015
Adzenys XR-ODTamphetamine	Amphetamine 12.5 mg/1	Tablet, Orally disintegratingOral	Neos Therapeutics Brands, LLC	70165-020
Adzenys XR-ODTamphetamine	Amphetamine 15.7 mg/1	Tablet, Orally disintegratingOral	Neos Therapeutics Brands, LLC	70165-025
Adzenys XR-ODTamphetamine	Amphetamine 18.8 mg/1	Tablet, Orally disintegratingOral	Neos Therapeutics Brands, LLC	70165-030